Full-Time

Director – AI Product / Program Delivery

Posted on 7/4/2026

Deadline 7/22/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$162.9k - $271.5k/yr

+ Bonus + Equity

No H1B Sponsorship

Phoenixville, PA, USA + 2 more

More locations: Groton, CT, USA | New York, NY, USA

In Person

Onsite 2.5 days per week required.

Category
Business & Strategy (2)
,
Required Skills
Product Management
Risk Management

Get referred to Pfizer

Find people who can refer or advise you

Requirements
  • Bachelor’s degree with at least 8+ years of experience; OR a Master’s degree with more than 7+ years of experience; OR a Ph.D. with 5+ years of experience.
  • Experience with program or product management, delivery, or technical program cross-functional team management, including complex multi-stakeholder programs.
  • Experience building a business case and operating credibly with executive-level leadership.
  • Demonstrated ability to run technical delivery programs end-to-end — plans, milestones, dependencies, and risk.
  • Working fluency in AI / technical delivery — able to engage credibly with engineers on what is being built and why.
  • Experience coordinating vendors, contractors, and internal teams against scope, schedule, and budget.
  • Strong facilitation and stakeholder management, including with senior executives.
  • Excellent written and verbal communication; ability to make complexity legible.
Responsibilities
  • Vision & Strategy — Know the commercial strategy well enough to judge which problems are worth solving, set the direction for the initiative, and keep the work anchored to the outcomes the business actually cares about.
  • Business Case & Commercial Logic — Build the business case and carry it forward. Size the opportunity, define the bet, and make the call on where to invest and where to stop. You produce this — you don't commission it.
  • AI-First Leadership — Lead this as an AI-first effort, not a conventional program with AI added on top. Push the team to reach for AI where it changes the shape of the work, hold automation and intelligence as the default rather than the exception, and set the ways of working the rest of the portfolio can learn from.
  • Business Outcomes — Own the result and the work that gets there. Tie the initiative to commercial outcomes and drive measurable movement on them. When something isn't working, you're close enough to the work to catch it and change course
  • Hybrid Team & Delivery — Lead a team that is part people, part agents, and produce alongside it. Decide what humans do, what agents do, and how they work together — then build. You set the operating model and you stay in the work
  • Program & Delivery Management — Own the initiative plan and key milestones. Drive cadence and ceremonies, track progress against goals, manage dependencies and critical path, and keep delivery on schedule.
  • Reporting & Communication — Produce clear, honest status for the VP, business sponsor, and governance forums. Maintain the single source of truth on status, decisions, and risks.
Desired Qualifications
  • Experience in commercial pharma or regulated environments, and familiarity with promotional-review and compliance workflows.
  • Experience with agile delivery and modern program-management and collaboration tooling.
  • Exposure to AI- or data-driven products and delivery.
  • PMP, agile, or equivalent certification

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Obesity asset MET097i targets 2028 launch to offset $17B–$18B patent cliff losses.
  • Oncology revenues grew 7% to $3.8B in Q1 2026, driven by Padcev and Lorbrena.
  • FDA approval for Padcev-Keytruda expands bladder cancer treatment to earlier disease stages.

What critics are saying

  • Eliquis, Ibrance, Xtandi, and Prevnar 13 lose exclusivity by 2028, dropping $17B revenue.
  • Sigvotatug vedotin failed Phase 3 for lung cancer, weakening Seagen's oncology pipeline de-risking.
  • Cash flow fell $700M short of covering dividends in 2025, pressuring the 7% yield.

What makes Pfizer unique

  • Pfizer leads with four marketed antibody-drug conjugates from its $43B Seagen acquisition.
  • The company offers a monthly GLP-1 obesity drug, berobenatide, from Metsera.
  • Patent-protected Padcev-Keytruda regimen is the first platinum-free option for bladder cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE